Title:
Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)
View
Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)
View
Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)
View
Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)
View
Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01)
View
Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)
View
Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)
View
Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)
Indication:
Breast Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)
View
Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
View
Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)
View
Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)
Indication:
Leukemia
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 study of I-Dxd in subjects with relapsed SCLC
View
Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 study of I-Dxd in subjects with relapsed SCLC
View
Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 study of I-Dxd in subjects with relapsed SCLC
View
Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Paris
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma
View
Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Palestine Cancer Center
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Longview Cancer Center
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Longview
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: III